Iranian Blood Transfusion Organization Research Center

Tehrān, Iran

Iranian Blood Transfusion Organization Research Center

Tehrān, Iran
Time filter
Source Type

Togha M.,Tehran University of Medical Sciences | Jahanshahi M.,Golestan University of Medical Sciences | Alizadeh L.,Shefa Neuroscience Research Center | Jahromi S.R.,Shefa Neuroscience Research Center | And 7 more authors.
Molecular Neurobiology | Year: 2017

The immunomodulatory and anti-inflammatory properties of bone marrow-derived mesenchymal stem cells (BM-MSCs) have been considered as an appropriate candidate for treatment of autoimmune diseases. Previous studies have revealed that treatment with BM-MSCs may modulate immune responses and alleviate the symptoms in experimental autoimmune encephalomyelitis (EAE) mice, an animal model of multiple sclerosis. Therefore, the present study was designed to examine immunomodulatory effects of BM-MSCs in the treatment of myelin oligodendrocyte glycoprotein (MOG) 35-55-induced EAE in C57BL/6 mice. MSCs were obtained from the bone marrow of C57BL mice, cultured with DMEM/F12, and characterized with flow cytometry for the presence of cell surface markers for BM-MSCs. Following three passages, BM-MSCs were injected intraperitoneally into EAE mice alone or in combination with rapamycin. Immunological and histopathological effects of BM-MSCs and addition of rapamycin to BM-MSCs were evaluated. The results demonstrated that adding rapamycin to BM-MSCs transplantation in EAE mice significantly reduced inflammation infiltration and demyelination, enhanced the immunomodulatory functions, and inhibited progress of neurological impairments compared to BM-MSC transplantation and control groups. The immunological effects of rapamycin and BM-MSC treatments were associated with the inhibition of the Ag-specific lymphocyte proliferation, CD8+ cytolytic activity, and the Th1-type cytokine (gamma-interferon (IFN-γ)) and the increase of Th-2 cytokine (interleukin-4 (IL-4) and IL-10) production. Addition of rapamycin to BM-MSCs was able to ameliorate neurological deficits and provide neuroprotective effects in EAE. This suggests the potential of rapamycin and BM-MSC combined therapy to play neuroprotective roles in the treatment of neuroinflammatory disorders. © 2016, Springer Science+Business Media New York.

Karimi G.,High Institute for Research and Education in Transfusion Medicine | Karimi G.,Iranian Blood Transfusion Organization Research Center | Gharehbaghian A.,Shahid Beheshti University of Medical Sciences | Fallah Tafti M.,High Institute for Research and Education in Transfusion Medicine | Vafaiyan V.,High Institute for Research and Education in Transfusion Medicine
Transfusion Medicine and Hemotherapy | Year: 2013

The risk of transfusion-transmitted infections has been greatly reduced by improvements in donor screening and testing. However, newly recognized blood-borne infectious agents can be threats to blood safety. In order to evaluate the prevalence some of these agents in blood donors, a systematic review was conducted. Data were obtained from published papers related to HGV, Torque Teno virus (TTV), HTLV, West Nile virus (WNV) and SEN virus (SEN-V). Based on these studies, the prevalence of HGV varied from 1 to 8.6% for anti-E2 and from 0 to 4.8% for HGV RNA. The prevalence of TTV DNA and HTLV-I varied from 2.7 to 79.5% and from 0.013 to 2.3%, respectively. The WNV-specific IgM antibody and WNV RNA are negative in blood donors. Prevalence rates of SEN-V in Iranian blood donors range from 23 to 90.8%. Consequences of these infectious agents for blood safety are different. Thus, the need to perform laboratory screening as well as effectiveness and efficiency of laboratory tests depend on pathogenicity level and epidemiological conditions of emerging infections. However, being prepared based on the current level of risk and interventions to reduce the risk can be effective in reducing the potential threat for blood supply. © 2013 S. Karger GmbH, Freiburg.

Mahjoubi F.,Iranian Blood Transfusion Organization Research Center | Mahjoubi F.,Iran National Institute of Genetic Engineering and Biotechnology | Razazian F.,Iranian Blood Transfusion Organization Research Center
Journal of Assisted Reproduction and Genetics | Year: 2012

Backgrounds While XXY aneuploidy is the most common disorder of sex chromosomes in men, complex chromosomal rearrangements (CCRs) are rare in humans. Case description Here we describe clinical and cytogenetic findings in a male referred to our cytogenetic laboratory by an infertility clinic. The patient's age was 35 at the time of referral. Total azoospermia was confirmed on semen analysis. Results The karyotype of peripheral blood showed 47,XXY, t(1;3;5)(p22;q29;q22). The mother had the same CCRs. Discussion To our best of our knowledge this is the first case of 47,XXY with CCRs. We think it is important to report such a unique chromosomal occurrence. © 2012 The Author(s).

Cheraghali A.M.,Iranian Blood Transfusion Organization Research Center | Abolghasemi H.,Iranian Blood Transfusion Organization Research Center | Abolghasemi H.,Baqiyatallah Medical Sciences University
Biologicals | Year: 2010

Plasma contains several therapeutically important proteins. Currently more than 25 of them are commercially available to treat life-threatening diseases. Some of these medicines already included in the WHO Model List of Essential Medicines indicating their importance from a global perspective. However, unfortunately due to very high cost of treatment with plasma-derived medicines, these clinically precious tools are not affordable for a majority of the patients living in developing countries. There are some options available for securing accessibility to these medicines. These include local production, importation and contract fractionation of locally produced plasma. Although local production of plasma-derived medicines and/or importation of these medicines might be a practical approach to respond to the needs for these medicines, in recent years several countries have used contract fractionation of locally produced plasma as a very effective approach for improving availability and affordability of plasma-derived medicines in their national market. © 2009 The International Association for Biologicals.

Haghighipour N.,Pasteur Institute of Iran | Heidarian S.,Pasteur Institute of Iran | Heidarian S.,University of Tehran | Shokrgozar M.A.,Pasteur Institute of Iran | Amirizadeh N.,Iranian Blood Transfusion Organization Research Center
Cell Biology International | Year: 2012

Both fetal and adult skeletal muscle cells are continually being subjected to biomechanical forces. Biomechanical stimulation during cell growth affects proliferation, differentiation and maturation of skeletal muscle cells. Bone marrow-derived hMSCs [human MSCs (mesenchymal stem cells)] can differentiate into a variety of cell types, including skeletal muscle cells that are potentially a source for muscle regeneration. Our investigations involved a 10% cyclic uniaxial strain at 1 Hz being applied to hMSCs grown on collagen-coated silicon membranes with or without IGF-I (insulin-like growth factor-I) for 24 h. Results obtained from morphological studies confirmed the rearrangement of cells after loading. Comparison of MyoD and MyoG mRNA levels between test groups showed that mechanical loading alone can initiate myogenic differentiation. Furthermore, comparison of Myf5, MyoD, MyoG and Myf6 mRNA levels between test groups showed that a combination of mechanical loading and growth factor results in the highest expression of myogenic genes. These results indicate that cyclic strain may be useful in myogenic differentiation of stem cells, and can accelerate the differentiation of hMSCs into MSCs in the presence of growth factor. © The Author(s) Journal compilation. © 2012 International Federation for Cell Biology.

Safa M.,Tehran University of Medical Sciences | Kazemi A.,Tehran University of Medical Sciences | Zand H.,Shahid Beheshti University | Azarkeivan A.,Iranian Blood Transfusion Organization Research Center | And 2 more authors.
Apoptosis | Year: 2010

Exposure of cells to chemotherapeutic drug doxorubicin, a DNA-damaging agent, induces an increase in the levels and activity of the wild-type p53 protein. Less well appreciated was the effect of cAMP levels on posttranslational modifications of p53 in response to doxorubicin. Here we show that elevation of cAMP in pre-B acute lymphoblastic leukemia NALM-6 cells significantly attenuated phosphorylation state of p53 at Ser6, Ser9, Ser15, Ser20, Ser37, Ser46 and Ser392 upon exposure to doxorubicin. Increased cAMP levels also shifted the ratio of the death promoter to death repressor genes via alteration of Bcl-2 and Bax proteins expression. In conclusion, our results suggest that activation of cAMP-signaling system may repress p53-dependent apoptosis in malignant cells exposed to doxorubicin. © 2009 Springer Science+Business Media, LLC.

Alavian S.-M.,Baqiyatallah Medical Sciences University | Tabatabaei S.V.,Baqiyatallah Medical Sciences University | Keshvari M.,Iranian Blood Transfusion Organization Research Center | Behnava B.,Baqiyatallah Medical Sciences University | And 3 more authors.
Liver International | Year: 2010

Background/aims: Chronic hepatitis C virus infection (HCV) is a major comorbidity in patients with haemophilia. Peginterferon alpha and ribavirin is current standard anti-HCV thrapy but there is little information about safety and efficacy of peginterferon α-2a and ribavirin combination therapy in these patients. Material and methods: In an open-label single-treatment arm cohort study, 367 haemophilia patients seronegative for hepatitis B and human immunodeficiency virus markers and chronically infected with HCV (HCV RNA > 50 IU/ml for at least 6 months) received 180 mg of Pegasyss® and 800-1200 μg of ribavirin according to body weight. Genotypes 1 and 4, mixed and untypable infections were treated for 48 weeks, while genotypes 2 and 3 were treated for 24 weeks. The efficacy of therapy was expressed as sustained virological response (SVR). Results: Two hundred and twenty-five subjects [61%, 95% confidence interval (CI) 56-66] achieved SVR, 66 patients relapsed and 30 subjects did not respond and nine patients developed breakthrough during treatment. In a multivariate logistic regression model, age < 24 odds ratio (OR) = 1.8 (95% CI 1.1-3.1), genotype non-1 OR= 1.8 (95% CI 1.1-3.2), BMIo25 OR= 2.1 (95% CI 1.3-3.3) and HCV RNA < 600 000 IU/ml OR= 1.7 (95% CI 1.1-3.2) were independent predictors of SVR. Eight patients discontinued the treatment because of persistent neutropaenia and 22 subjects were dropped out because of intractable side effects. Furthermore, two patients died during treatment and five were lost to follow-up after treatment cessation. Conclusions: Peginterferon alpha-2a in combination with weight-based ribavirin has SVR rate of 51% for genotype 1 and 71% for genotype non-1 infections in haemophilia patients. Age < 24, BMI < 25, viral load 600 000 IU/ml and genotype non-1 are the major determinants of SVR achievement in these patients. © 2010 John Wiley & Sons A/S.

Abolghasemi H.,International Law MA Graduate | Hosseini-Divkalayi N.S.,International Law MA Graduate | Seighali F.,Iranian Blood Transfusion Organization Research Center
Asian Journal of Transfusion Science | Year: 2010

Dramatic increase in blood usage and critical seasonal blood shortages are faced by various countries. Countries which previously reached 100% voluntary nonremunerated donation have been led to offer different kinds of incentives to recruit blood donors and meet their blood demands. In some cases, these incentives are considered monetary and are in complete contrast with International standards like World Health Organization (WHO). It seems that attitudes toward sole dependency on nonremunerated voluntary blood donation have been changed in recent years and experts in some developed countries are reevaluating partial reliance on paid donation. On the other hand, besides the effects of such incentives on blood safety, several economic and psychological studies have shown that incentives have discouraging effects on pro-social behaviors like blood donation and will reduce the number of blood donors in long term. With regard to the results of such studies, it seems that implementing incentive-based blood donor recruitment programs to meet blood requirements by some countries is becoming a challenge for blood banks.

Minoo A.,Iranian Blood Transfusion Organization Research Center | Nader R.,Tehran University of Medical Sciences
Blood Coagulation and Fibrinolysis | Year: 2013

An 82-year-old man referred to our medical ward because of epistaxis and melena was found to have 12 Bethesda units of factor V inhibitor. He was managed for bleeding with supportive care, followed by corticosteroid therapy. The bleeding completely stopped 1 week after corticosteroid therapy. Medical history revealed dysphagia during the past 6 months and further evaluation brought to light a squamous cell carcinoma (SCC) in the esophagus. This is the first case of an acquired factor V inhibitor developing in a patient with esophageal SCC without any other risk factors such as surgery. © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins.

Ali S.F.,Iranian Blood Transfusion Organization Research Center
Transfusion and Apheresis Science | Year: 2011

Preparation for storage may cause platelet activation. The quality of platelet concentrates plays an important role in transfusion therapy. Platelet concentrates are produced by different centrifugation methods; buffy coat (buffy coat-derived platelet concentrates-BC) and plateletpheresis (apheresis-derived platelet concentrates-APC). Their quality was assessed using the following parameters: platelet, WBC and RBC counts pH, volume, platelet factor 4 (PF4) and Annexin V. The present paper compares the quality of both platelet preparations in vitro. In this experimental study, 30 platelet concentrates were harvested with the Haemonetics MCS plus and 30 units via the buffy coat (BC) method. The percentages of Annexin V expression, PF4 levels, platelet, WBC and RBC counts, pH and volume were measure immediately after collection and after 3. days of storage. During storage for up to 3. days, BC units displayed, no significant pH or RBC, difference in comparison with apheresis preparations (p> 0.05). During storage for up to 3. days, BC units displayed a significant increase in the PF4 and Annexin V expression, compared to the apheresis preparations on day three (p< 0.05).The kinetics of PF4 and Annexin V levels are influenced by the method used to prepare platelets for storage. The different levels of PF4 and Annexin V in BCs and APCs clearly demonstrates a progressive activation of BC platelets exceeding that of APC. However, in vivo studies should be performed to confirm these findings. © 2010 Elsevier Ltd.

Loading Iranian Blood Transfusion Organization Research Center collaborators
Loading Iranian Blood Transfusion Organization Research Center collaborators